Prostate cancer: Focal One®, a revolutionary treatment
 
Geneva:
+4122 840 33 34
 
Moscow:
+7(903)720 80 57

Prostate cancer: Focal One®, a revolutionary treatment

Date: 14/01/2021
Last edited: 21/01/2021

Focal One® is a computer-controlled medical device for the treatment of localised prostate cancer by focused ultrasound (HIFU = High Intensity Focused Ultrasound). The energy is delivered via an endorectal probe. The ultrasound waves travel through the rectal wall and are focused on a part of the prostate. This focusing produces intense heat, resulting in tissue destruction within the target area. The treatment lasts between 30 minutes and 2 hours and can be performed under loco-regional anaesthesia.

Focal One® is a non-invasive treatment option that allows for a precise, local treatment in one session, that can be repeated if necessary, with a short hospital stay and few side effects. In the event of incomplete results, the choice of therapeutic options is wide and includes retreatment with Focal One®.

Focal One® may be indicated as:

  • a first line option for patients with localised cancer, stage T1-T2 (Gleason 6 or 7, PSA less than 15), according to their age and general condition.
  • a salvage therapy option for patients with local recurrence of prostate cancer initially treated by radiotherapy.

HIFU for prostate cancer

HIFU uses a high intensity convergent ultrasound beam generated by piezoelectric transducers. This focusing of ultrasound waves into one point greatly increases the temperature around the focal point, thus resulting in tumour destruction i.e. pathological biological tissue.

The application of HIFU for prostate cancer treatment involves focusing high intensity focused ultrasound to destroy, by heat, prostatic tissue affected by cancer, without damaging surrounding tissue. This technique is non-invasive because it avoids incision, allows loco-regional anaesthesia and limits the characteristic complications of prostate cancer treatment (incontinence or impotence).

Clinical results

In 2013 and 2014, two prospective cohort studies demonstrated the long-term (10 years) results of whole gland HIFU as a first-line option and have validated its effectiveness: according to the cancer risk, the specific survival rate at 10 years is between 92 and 99%; survival rate without metastases at 10 years is between 86% and 100%. These results, which are completely comparable to the best radical surgery results, demonstrate that HIFU is an effective first-line treatment option for localised prostate cancer.

Comments
Articles
Patient registration form
Topics
Examination Incorpore
age management
Anti-aging
prevention
weight management
detoxification
weight loss
nutrition
oncology
cancer
allergy
dermatology
skin
oncology treatment
diagnosis
cardiology
heavy metal
immunology
check-up
Fertility
cosmetology
skincare
stem cells
Genetics
Blood pressure
DNA
gynecology
pain
liver detox
heart MRI
Examination partner centres
infertility
Allergology
chelation
covid19
liver
urology
Allergology treatment
gastroenterology
Sleep
tinnitus
probiotics
pregnancy
joints
radiology
headache
Hepatitis C
Apnea
NAD+
obstetrics
mesotherapy
rehabilitation
arsenic
candida
andropause
immune system
neurology
breast cancer
immunotherapy
research
PRP
menopause
rhesus factor
pancreas
knee
oncoloy
propofole
magnesium
hand
cellulite
nephrology
R-loops
abdominal pain
migraine
reconstruction
erectile dysfunction
diet
Omega-3
hormones
hip
shoulder
telomere
obstertics
blood test
general surgery
back pain
colonoscopy
mercury
flu
mastectomy
regeneration
water
Treatment programs
kidney
proctology
cellmen
reflexology
hyaluronic acid
acnea
oral checkup
pomegranate
cellcosmet
sexuality
gastroscopy
migraines
dermatitis
liquid biopsy
rheumatology
vitamin K
anti-aging
gastritis
chronic headaches
orthopedics
food
preventiion
ulcer
endocrinology
Дерматология
vitamin b12
herniated disc
endometriosis
digestion
stress
intestinal flora
beauty
brain surgery awake
acne
ophthalmology
depression
exercise
beau-rivage
nutrigenomics
psoriasis
narcosis
LED therapy
flu vaccine
plastic surgery
iron
sports
excimer laser
lungs
food intolerances
second opinion
cholesterol
light therapy
biopsy
pneumology
mammography
diabetes
sugar